Home/Filings/4/0001387131-21-006822
4//SEC Filing

GLAXOSMITHKLINE PLC 4

Accession 0001387131-21-006822

$GSKCIK 0001806952other

Filed

Jun 22, 8:00 PM ET

Accepted

Jun 23, 6:14 PM ET

Size

7.8 KB

Accession

0001387131-21-006822

Insider Transaction Report

Form 4
Period: 2021-06-21
Transactions
  • Conversion

    Common Stock

    2021-06-21+30,253,18930,253,189 total(indirect: See Footnote)
  • Conversion

    Series AA Preferred Stock

    2021-06-2130,253,1890 total(indirect: See Footnote)
    Common Stock (30,253,189 underlying)
Footnotes (2)
  • [F1]The Series AA Preferred Stock automatically converted into common stock on a 1-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
  • [F2]The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").

Issuer

Lyell Immunopharma, Inc.

CIK 0001806952

Entity typeother
IncorporatedUnited Kingdom

Related Parties

1
  • filerCIK 0001131399

Filing Metadata

Form type
4
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 6:14 PM ET
Size
7.8 KB